Drug Trial Radar · NCT02518516
High Potency Statins and Acute Kidney Injury
Last checked: Nov 19, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,067,639
Actual
Start
Jan 2011
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- Canadian Network for Observational Drug Effect Studies, CNODESAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Drug Safety and Effectiveness Network, Canada; Canadian Institutes of Health Research (CIHR)
- First posted
- Aug 7, 2015
Design
- Study type
- Observational
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Statins are a class of cholesterol lowering medications that are prescribed for the prevention and treatment of cardiovascular disease. The purpose of this study is to determine if there is an excess risk of acute kidney injury (AKI) with high potency statins compared to low potency statins. The investigators will carry out separate population based cohort studies using administrative health care databases in nine jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a statin, with follow-up until hospitalization for AKI. Analyses will be done separately for groups of patients with and without chronic kidney disease. The results from the separate sites will be combined in a meta-analysis to provide an overall assessment of the risk of AKI in new statin users.
Conditions
- Hypercholesterolemia
Interventions
Rosuvastatin (≥10 mg)Drug
Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date).
Atorvastatin (≥20 mg)Drug
Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Simvastatin (≥40 mg)Drug
Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
FluvastatinDrug
Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
PravastatinDrug
Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
LovastatinDrug
Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Atorvastatin (<20mg)Drug
Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Simvastatin (<40 mg)Drug
Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days). Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients hospitalized for acute kidney injuryTime frame: Patients will be followed from the date of study cohort entry until either hospitalization for acute kidney injury or censoring (whichever occurs first), or will be assessed for up to 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dept. of Anesthesiology, Pharmacology & Therapeutics (APT), University of British Columbia
Vancouver, British Columbia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.